Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs)

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 554, Issue 1-2, 2004, Pages 175-183

  Gorlov, Ivan P ^a   Gorlova, Olga Y ^a   Frazier, Marsha L ^a   Amos, Christopher I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ESE; exonic splicing enhancer; Exonic splicing enhancer; Missense mutations; NAS; nonsense associated altered splicing; open reading frame; ORF; p53; PCR; polymerase chain reaction; serine and arginine rich proteins; Splicing; SR

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER SUSCEPTIBILITY; CODON; DISEASE ASSOCIATION; EXON; GENE LOCATION; GENETIC ASSOCIATION; MISSENSE MUTATION; MUTATION RATE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN MOTIF; RNA SPLICING; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; ENHANCER ELEMENTS (GENETICS); EXONS; GENES, P53; MUTATION, MISSENSE; OPEN READING FRAMES; RNA SPLICING;

EID: 4344693159     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.04.014     Document Type: Article

References (46)

1. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:2002;607-614
2. Vihinen M., Arredondo-Vega F.X., Casanova J.L., Etzioni A., Giliani S., Hammarstrom L., Hershfield M.S., Heyworth P.G., Hsu A.P., Lahdesmaki A., Lappalainen I., Notarangelo L.D., Puck J.M., Reith W., Roos D., Schumacher R.F., Schwarz K., Vezzoni P., Villa A., Valiaho J., Smith C.I. Primary immunodeficiency mutation databases. Adv. Genet. 43:2001;103-188
3. Theophilus B.D., Enayat M.S., Williams M.D., Hill F.G. Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A. Haemophilia. 7:2001;381-391
4. Pollard A.J., Krainer A.R., Robson S.C., Europe-Finner G.N. Alternative splicing of the adenylyl cyclase stimulatory G-protein G alpha(s) is regulated by SF2/ASF and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and involves the use of an unusual TG 3′-splice Site. J. Biol. Chem. 277:2002;15241-15251
5. Moseley C.T., Mullis P.E., Prince M.A., Phillips J.A. III An exon splice enhancer mutation causes autosomal dominant GH deficiency. J. Clin. Endocrinol. Metab. 87:2002;847-852
6. Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am. J. Hum. Genet. 71:2002;625-631
7. Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30:2002;377-384
8. Cartegni L., Chew S.L., Krainer A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3:2002;285-298
9. Liu H.X., Zhang M., Krainer A.R. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev. 12:1998;1998-2012
10. Blencowe B.J. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem. Sci. 25:2000;106-110
11. Hastings M.L., Krainer A.R. Pre-mRNA splicing in the new millennium. Curr. Opin. Cell Biol. 13:2001;302-309
12. Graveley B.R. Sorting out the complexity of SR protein functions. RNA. 6:2000;1197-1211
13. Stojdl D.F., Bell J.C. SR protein kinases: the splice of life. Biochem. Cell Biol. 77:1999;293-298
14. Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9:2000;237-247
15. Liu H.X., Chew S.L., Cartegni L., Zhang M.Q., Krainer A.R. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell Biol. 20:2000;1063-1071
16. Z.Z. Cartegni, M.Q. Zhang, A.R. Krainer, ESEfinder web interface (1.1), http://www.exon.cshl.edu/ESE/, 2002.
17. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526
18. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer. 2:2002;277-288
19. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:2002;594-604
20. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456
21. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature. 404:2000;892-897
22. Brantley M.A. Jr., Worley L., Harbour J.W. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. Am. J. Ophthalmol. 133:2002;242-248
23. Robles A.I., Linke S.P., Harris C.C. The p53 network in lung carcinogenesis. Oncogene. 21:2002;6898-6907
24. Martin A.C., Facchiano A.M., Cuff A.L., Hernandez-Boussard T., Olivier M., Hainaut P., Thornton J.M. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum. Mutat. 19:2002;149-164
25. Morris S.M. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 511:2002;45-62
26. Selivanova G. Mutant p53: the loaded gun. Curr. Opin. Invest. Drugs. 2:2001;1136-1141
27. Hernandez-Boussard T., Rodriguez-Tome P., Montesano R., Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum. Mutat. 14:1999;1-8
28. Rodin S.N., Rodin A.S. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11927-11932
29. Rodin S.N., Rodin A.S., Juhasz A., Holmquist G.P. Cancerous hyper-mutagenesis in p53 genes is possibly associated with transcriptional bypass of DNA lesions. Mutat. Res. 510:2002;153-168
30. Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol. Cell Biol. 5:1985;1601-1610
31. Bullock A.N., Henckel J., Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 19:2000;1245-1256
32. Vogelstein B., Kinzler K.W. Tumour-suppressor genes. X-rays strike p53 again. Nature. 370:1994;174-175
33. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355
34. Seong J.Y., Han J., Park S., Wuttke W., Jarry H., Kim K. Exonic splicing enhancer-dependent splicing of the gonadotropin-releasing hormone premessenger ribonucleic acid is mediated by tra2alpha, a 40-kilodalton serine/arginine-rich protein. Mol. Endocrinol. 16:2002;2426-2438
35. Lam B.J., Hertel K.J. A general role for splicing enhancers in exon definition. RNA. 8:2002;1233-1241
36. Morgenstern B., Frech K., Dress A., Werner T. DIALIGN: finding local similarities by multiple sequence alignment. Bioinformatics. 14:1998;290-294
37. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:2002;7435-7451
38. Hendrich B., Bird A. Mammalian methyltransferases and methyl-CpG-binding domains: proteins involved in DNA methylation. Curr. Top. Microbiol. Immunol. 249:2000;55-74
39. Jones P.A. DNA methylation and cancer. Oncogene. 21:2002;5358-5360
40. Maquat L.E. NASty effects on fibrillin pre-mRNA splicing: another case of ESE does it, but proposals for translation-dependent splice site choice live on. Genes Dev. 16:2002;1743-1753
41. Dietz H.C., Valle D., Francomano C.A., Kendzior R.J. Jr., Pyeritz R.E., Cutting G.R. The skipping of constitutive exons in vivo induced by nonsense mutations. Science. 259:1993;680-683
42. Liu W., Qian C., Francke U. Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. Nat. Genet. 16:1997;328-329
43. Thompson T.E., Rogan P.K., Risinger J.I., Taylor J.A. Splice variants but not mutations of DNA polymerase beta are common in bladder cancer. Cancer Res. 62:2002;3251-3256
44. O'Neill J.P., Rogan P.K., Cariello N., Nicklas J.A. Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum. Mutat. Res. 411:1998;179-214
45. Babenko O.V., Saakian S.V., Brovkina A.F., Kozlova V.M., Strel'nikov V.V., Zaletaev D.V., Nemtsova M.V. Spectrum and frequencies of RB1 gene structural defects in retinoblastoma. Mol. Biol. (Mosk.). 36:2002;623-629
46. Holmila R., Fouquet C., Cadranel J., Zalcman G., Soussi T. Splice mutations in the p53 gene: case report and review of the literature. Hum. Mutat. 21:2003;101-102